BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17538525)

  • 1. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
    Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis.
    Mansueto M; Grimaldi A; Mangili G; Picchio M; Giovacchini G; ViganĂ² R; Messa C; Fazio F
    Eur J Cancer Care (Engl); 2009 Nov; 18(6):612-9. PubMed ID: 19549284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
    Wang YT; Huang G
    Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
    Krug B; Crott R; Roch I; Lonneux M; Beguin C; Baurain JF; Pirson AS; Vander Borght T
    Acta Oncol; 2010; 49(2):192-200. PubMed ID: 20059314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is 18F FDG PET-CT cost effective in lung cancer?
    Buscombe J; O'Rourke E
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):471-6. PubMed ID: 17428168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making.
    Remonnay R; Morelle M; Pommier P; Giammarile F; Carrère MO
    Int J Technol Assess Health Care; 2008; 24(2):212-20. PubMed ID: 18400125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada.
    Sloka JS; Hollett PD; Mathews M
    Med Sci Monit; 2004 May; 10(5):MT73-80. PubMed ID: 15114279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?
    Hayashi K; Abe K; Yano F; Watanabe S; Iwasaki Y; Kosuda S
    Ann Nucl Med; 2005 Jul; 19(5):393-8. PubMed ID: 16164196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care.
    Gordin A; Golz A; Keidar Z; Daitzchman M; Bar-Shalom R; Israel O
    Otolaryngol Head Neck Surg; 2007 Jul; 137(1):130-7. PubMed ID: 17599580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
    Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
    Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
    Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
    Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules.
    Ohno Y; Koyama H; Takenaka D; Nogami M; Maniwa Y; Nishimura Y; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2008 Jun; 27(6):1284-95. PubMed ID: 18504748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT.
    Wildi SM; Gubler C; Hany T; Petrowsky H; Clavien PA; Jochum W; Gerlach T; Fried M; Mullhaupt B
    J Clin Ultrasound; 2008 Jan; 36(1):20-6. PubMed ID: 17937421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
    Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
    Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
    Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
    J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
    Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
    Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
    Saif MW; Cornfeld D; Modarresifar H; Ojha B
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.